Drugmakers see a pricing blueprint in an $850,000 gene therapy


Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive - and effective - new medicines. Spark Therapeutics Inc plans to launch its recently approved Luxturna treatment for an inherited genetic mutation that causes blindness in March.



from Biotech News